Summary

Immune Thrombocytopenia (ITP) is an autoimmune-related bleeding disorder characterized by a low platelet count. The exact cause of ITP is still unclear; however, the pathophysiology of the disease can be contributed by an increased destruction of platelets, a decreased production of platelets, or both. Therefore, there might be multiple causes and mechanisms that can contribute to the disease. ITP can affect patients at all ages, but pediatric patients are likely to recover spontaneously while adult patients have a higher chance to develop into a chronic condition.

It is estimated that the value of the ITP market in the 7MM in 2015 was $928M, including sales of the major branded and off-label drugs commonly prescribed for ITP patients across the 7MM. The US is the largest contributor to the 7MM, with $587M in 2015, representing 63.3% of the market share. The 5EU and Japan contributed $281M and $60M in 2015, respectively, to the major ITP markets.

ITP market to grow during in the first half of the forecast period (2015-2025); however, sales will start to decline in 2022 in the US and projects that total ITP sales in 2025 will grow to $985M at a modest overall Compound Annual Growth Rate (CAGR) of 0.6%.

Major drivers of the growth of the ITP market over the forecast period include the following -

  • Increasing uptake and market penetration of marketed brands, Amgen’s Nplate (romiplostim) and Novartis’ Promacta/Revolade (eltrombopag), in both adult and pediatric ITP populations.
  • Rising diagnosed prevalence of adult ITP, and hence a rising treated population.
  • Launch of Rigel Pharmaceuticals’ fostamatinib, which will offer a new mechanism of action (MOA) for ITP treatment.



Companies are looking into drugs with novel MOA, which may offer hope to improve response rate and safety. It is identified that two promising approaches: spleen tyrosine kinase (Syk) inhibitors, including the Phase III fostamatinib, and CD40/CD40 ligand antagonists. As Rigel has managed to complete two pivotal Phase III trials for fostamatinib, It is expected that the drugs offering new MOAs to be essential for companies to successfully develop new ITP therapies moving forward.

The report "OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025", provides an overview of ITP, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

In particular, this report provides the following analysis -

  • Annualized ITP therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (including pediatric, adult primary, and adult secondary), forecast from 2015 to 2025.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ITP therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for ITP therapy. The most promising candidate in Phase III development is profiled.
  • Analysis of the current and future market competition in the global ITP therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.



Companies mentioned in this report: Amgen, Bristol-Myers Squibb, Eisai, Genosco, GlaxoSmithKline, Gliknik, Hansa, Hoffmann La-Roche, Immunomedics, Jiangsu Hengrui, Kyowa Hakko Kirin, Ligand Pharmaceuticals, Merck & Co., Momenta, Novartis, PBM Capital, Pfizer, Protalex, Rigel Pharmaceuticals, UCB Biopharma.


Scope

  • Overview of ITP, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized ITP therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (including pediatric, adult primary, and adult secondary), forecast from 2015 to 2025.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ITP therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for ITP therapy. The most promising candidate in Phase III development is profiled.
  • Analysis of the current and future market competition in the global ITP therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.




Reasons To Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global ITP therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ITP therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.